Cart
sales@molnova.com
LY2880070
CAS No. 1375637-35-6
LY2880070( —— )
Catalog No. M23534 CAS No. 1375637-35-6
LY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 120 | In Stock |
|
| 5MG | 114 | In Stock |
|
| 10MG | 179 | In Stock |
|
| 25MG | 352 | In Stock |
|
| 50MG | 518 | In Stock |
|
| 100MG | 737 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY2880070
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy.
-
DescriptionLY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1375637-35-6
-
Formula Weight381.43
-
Molecular FormulaC19H23N7O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc(cc1)nc(OC)c1-c1cc(Nc2cncc(O[C@H]3CNCCC3)n2)n[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
GDC0575 monohydrochl...
GDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.
-
Monalizumab
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
-
PHI-101
PHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.
